Speaker Profile

COO, MMRF

Biography
Michael Andreini joined the MMRF as the Chief Operating Officer in 2019, and is responsible for overseeing day-to-day operations, strategic programs, and alliances across the foundation. Michael brings over 12 years of strategic consulting and operational experience in the life sciences industry. Prior to joining the MMRF, Michael was an Associate Principal at IQVIA in the consulting services organization where he led complex engagements for biopharma, medical device, and non-profit organizations across diverse solution areas including commercial assessments, portfolio analysis, R&D and launch strategy, and operational execution. Before joining IQVIA, Michael worked at Fuld & Company, a boutique consulting firm specializing in competitive intelligence and strategy, and prior to that, at Siemens Healthcare Diagnostics in the Global technical Operations group where he resolved technical issues for immunoassay reagents and systems. Michael earned a B.A. in chemistry with a minor concentration in economics from Colgate University.


AI and Data Sciences Showcase:
MMRF

A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for every multiple myeloma patient by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer.

Innovation Of Patient-Centered Research Initiatives: MMRF CureCloud
The first-of-its-kind, innovative MMRF CureCloud research study features direct-to-patient enrollment, the first at-home CLIA-grade cfDNA sequencing test for myeloma, and real-world EHR data collection to deliver real-time insights back to patients and their physicians to inform clinical decision-making.

 Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2021 AI Company Showcase will provide a 15-minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.